130 related articles for article (PubMed ID: 36811581)
1. Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma.
Wächter S; Knauff F; Roth S; Keber C; Holzer K; Manoharan J; Maurer E; Bartsch DK; Di Fazio P
Cancer Invest; 2023 Apr; 41(4):405-421. PubMed ID: 36811581
[TBL] [Abstract][Full Text] [Related]
2. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
Zhu W; Xie B
Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines.
Shi XZ; Zhao S; Wang Y; Wang MY; Su SW; Wu YZ; Xiong C
Drug Des Devel Ther; 2023; 17():1889-1906. PubMed ID: 37397788
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
5. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
6. Capsaicin inhibits the stemness of anaplastic thyroid carcinoma cells by triggering autophagy-lysosome mediated OCT4A degradation.
Wu L; Xu S; Cheng X; Zhang L; Wang Y; Wu J; Bao J; Yu H; Lu R
Phytother Res; 2022 Feb; 36(2):938-950. PubMed ID: 35076979
[TBL] [Abstract][Full Text] [Related]
7. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
[TBL] [Abstract][Full Text] [Related]
10. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
11. Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis.
Champa D; Orlacchio A; Patel B; Ranieri M; Shemetov AA; Verkhusha VV; Cuervo AM; Di Cristofano A
Oncotarget; 2016 Jun; 7(23):34453-71. PubMed ID: 27144341
[TBL] [Abstract][Full Text] [Related]
12. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Anticancer Activity of
Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo.
Kim SY; Kim SM; Chang H; Chang HS; Park CS; Lee YS
Head Neck; 2020 Dec; 42(12):3678-3684. PubMed ID: 32896015
[TBL] [Abstract][Full Text] [Related]
17. Anti-Proliferative Effect of Radiotherapy and Implication of Immunotherapy in Anaplastic Thyroid Cancer Cells.
Wächter S; Roth S; Gercke N; Schötz U; Dikomey E; Engenhart-Cabillic R; Maurer E; Bartsch DK; Di Fazio P
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374179
[TBL] [Abstract][Full Text] [Related]
18. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
19. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
Hegedűs L; Rittler D; Garay T; Stockhammer P; Kovács I; Döme B; Theurer S; Hager T; Herold T; Kalbourtzis S; Bankfalvi A; Schmid KW; Führer D; Aigner C; Hegedűs B
Pathol Oncol Res; 2020 Oct; 26(4):2523-2535. PubMed ID: 32591993
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
